| MeSH term | MeSH ID | Detail |
|---|---|---|
| Insulin Resistance | D007333 | 99 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Hypertension | D006973 | 115 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Hemolysis | D006461 | 131 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Edema | D004487 | 152 associated lipids |
| Colonic Neoplasms | D003110 | 161 associated lipids |
| Adenocarcinoma | D000230 | 166 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| van Duijnhoven E et al. | The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. | 1998 | Transplant. Proc. | pmid:9636515 |
| Christiaans M et al. | Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. | 1998 | Transplant. Proc. | pmid:9636516 |
| Sato S et al. | Specificity of therapeutic drug monitoring of tacrolimus in kidney transplant patients. | 1998 | Transplant. Proc. | pmid:9636517 |
| Uchida K et al. | Decreasing pancreatic toxicity of tacrolimus by dosage reduction. | 1998 | Transplant. Proc. | pmid:9636518 |
| Rostaing L et al. | Early posttransplantation renal hemodynamics in FK 506-treated kidney recipients with or without prior induction therapy. | 1998 | Transplant. Proc. | pmid:9636519 |
| Rostaing L et al. | Influence of early FK 506 trough levels on glomerular hemodynamics at 3 months in kidney transplant recipients. | 1998 | Transplant. Proc. | pmid:9636520 |
| Morris-Stiff G et al. | Pharmaco-economic study of FK 506 (Prograf) and cyclosporine A Neoral in cadaveric renal transplantation. | 1998 | Transplant. Proc. | pmid:9636521 |
| Mendez R | FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group. | 1998 | Transplant. Proc. | pmid:9636522 |
| Vanrenterghem Y et al. | Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. | 1998 | Transplant. Proc. | pmid:9636523 |
| Claesson K et al. | Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. | 1998 | Transplant. Proc. | pmid:9636524 |
| Morris-Stiff G et al. | Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. | 1998 | Transplant. Proc. | pmid:9636525 |
| Woodle ES et al. | Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group. | 1998 | Transplant. Proc. | pmid:9636526 |
| Undre NA et al. | Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation. | 1998 | Transplant. Proc. | pmid:9636527 |
| Kumar MS et al. | ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis. | 1998 | Transplant. Proc. | pmid:9636549 |
| Neylan JF | Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. | 1998 | Transplant. Proc. | pmid:9636551 |
| Fitzsimmons WE et al. | Demographic considerations in tacrolimus pharmacokinetics. | 1998 | Transplant. Proc. | pmid:9636552 |
| Shapiro R et al. | Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. | 1998 | Transplant. Proc. | pmid:9636557 |
| Grewal HP et al. | Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. | 1998 | Transplant. Proc. | pmid:9636558 |
| Rossi G et al. | Three-year follow-up of low dose tacrolimus oral therapy after liver transplantation: a single-centre experience. | 1998 | Transplant. Proc. | pmid:9636562 |
| Samuel D et al. | Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation. | 1998 | Transplant. Proc. | pmid:9636563 |